title: Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.
abstract: We assessed the risk of clinically significant drug interactions in patients receiving antiretrovirals, and their recognition by physicians. Clinically significant drug interactions were recorded in 27% of 159 patients, with 15% of interactions potentially lowering antiretroviral concentrations. Risk of clinically significant drug interactions was significantly related to receipt of protease inhibitors. Only 36% of clinically significant drug interactions were correctly identified by physicians.
authors.affiliation: Department of Genitourinary Medicine, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.
authors.forename: John G
authors.initials: JG
authors.lastname: Evans-Jones
authors.forename: Lucy E
authors.initials: LE
authors.lastname: Cottle
authors.forename: David J
authors.initials: DJ
authors.lastname: Back
authors.forename: Sara
authors.initials: S
authors.lastname: Gibbons
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Beeching
authors.forename: Peter B
authors.initials: PB
authors.lastname: Carey
authors.forename: Saye H
authors.initials: SH
authors.lastname: Khoo
mesh_terms: D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006302:Health Services Research; D006801:Humans; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents